News Releases

View all Historical Press Releases

Month Year

Investor Alerts

Dec 8, 2016

Soligenix Announces Investor Webcast Event: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis

Friday, December 16, 2016, from 8:30-9:30 am ET

Princeton, NJ – December 8, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Dec 8, 2016

Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Study data supports advancing development to pivotal Phase 2b/3 program

Princeton, NJ – December 8, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Nov 10, 2016

Soligenix Announces Recent Accomplishments and Third Quarter 2016 Financial Results

Highlighted by Revenues of $3.0 Million

Princeton, NJ – November 10, 2016 – Soligenix, Inc. (OTCQB: SNGX (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 25, 2016

Soligenix Receives European Medicines Agency Designation as Small and Medium Enterprise

Princeton, NJ – October 25, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 18, 2016

Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Positive Clinical Results Consistent with Preclinical Data

Princeton, NJ – October 18, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 17, 2016

Soligenix to Receive $530,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Princeton, NJ – October 17, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 13, 2016

Soligenix Announces Poster Presentations from its Gastrointestinal Acute Radiation Syndrome Program at the 2016 Radiation Research Society Meeting

Princeton, NJ – October 13, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 11, 2016

Soligenix Announces Poster Presentation of its Ricin Vaccine and Dusquetide Orphan Programs at the 2016 NORD Rare Diseases and Orphan Products Breakthrough Summit

Princeton, NJ – October 11, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 7, 2016

Soligenix Announces Reverse-Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market

Princeton, NJ – October 7, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Sep 15, 2016

Soligenix to Present at 2016 Aegis Growth Conference

Princeton, NJ – September 15, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...

Show per page